Bruine de Bruin offers advice on how people can manage risks from wildfire smoke exposure
Virat Agrawal, PhD, MS
Virat Agrawal is policy researcher specializing in health policy and economics. His current research focuses on how macro-level shocks, public policy and regulations affect health outcomes, economic well-being and quality of life. His research on the spillover effects of COVID-19-era policies has been featured in prominent media outlets, including The Economist, WSJ-MarketWatch, The Washington Times, and others. Virat…
Amanda Chen, PhD
Amanda Chen is an Assistant Professor at the USC Mann School of Pharmacy and Pharmaceutical Sciences. Her research uses quasi-experimental methods and administrative claims to evaluate the quality of and access to post-acute and long-term care for older adults. Chen’s current work focuses on payment systems to align incentives and quality, the clinical infrastructure in…
Race-Specific Provider Performance: Evidence from Black Lives Matter Protests
Dr. Haizhen Lin is Professor and Associate Chair of Business Economics and Public Policy at the Kelley School of Business, Indiana University, where she also holds the Jack R. Wentworth Professorship. In addition to her primary role at Kelley, she is a Research Associate at the National Bureau of Economic Research (NBER). Dr. Lin earned…
Comments to USTR on Foreign Nations Freeloading on American-Financed Innovation
The U.S. Trade Representative should address foreign countries’ discriminatory use of QALY-based drug pricing and ensure such practices aren’t imported into the U.S. healthcare system through most-favored nation policies.
A Diabetes Paradox: Better Health, But Still Out of Work
It will take more than just health improvements to address the poor economic prospects of many with diabetes.
From Wildfires to the World Stage: Angelenos Weigh in on Mobility, Sustainability and the Olympics in L.A.
This year’s LABarometer Mobility & Sustainability survey arrives at a pivotal moment—in the aftermath of the January wildfires and as L.A. prepares for the 2028 Olympics.
FDA staff cuts may undermine agency promises on “radical transparency” and fewer conflicts of interest, Kanter explains
Peer-to-Peer Prior Authorization: Is Physician Participation Ethical?
Physician reviewers can be seen as barriers to care or stewards of limited resources.
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
Part D plans are abruptly shifting more costs onto beneficiaries as they adjust to the IRA’s new cap on out-of-pocket spending.
Shifting Cost-Sharing Burden to Beneficiaries in Medicare Part D
Although the Inflation Reduction Act’s out-of-pocket Part D cap adds important protection for beneficiaries, its implementation incentivized plans to increase beneficiary exposure to cost sharing prior to reaching that limit.
Advancing the Science of Recruitment for Alzheimer’s Clinical Trials: Challenges and Opportunities
Forty leading experts in Alzheimer’s clinical trials examined key barriers to inclusive recruitment, emerging recruitment strategies, and policy recommendations during a two-day roundtable.
What RFK Jr. Gets Wrong About Conflicts of Interest
Not all financial conflicts are equal. A wholesale purge of CDC’s vaccine advisory panel may remove some members with industry ties, but it also may come at the expense of expertise and delay access for patients.
Duffy quoted on her research into hospitals expanding long-term payment plans
Kanter discusses the importance of vetting financial conflicts among CDC’s vaccine advisors
Why Do Americans Pay More for Prescription Drugs?
Senior Scholar Darius Lakdawalla explains the global economics of prescription drug pricing and outlines a better alternative to President Trump’s most-favored-nation executive order.
Agency Overreach Leaves Patients Untreated
Medicare’s Coverage with Evidence Development program is stifling patient access to innovative FDA-approved products, from heart valve replacements to PET scans for Alzheimer’s. It’s time for a major overhaul.
Grogan quoted on the competitive threat the U.S. faces from Chinese biotech
Leveraging Corporate Tax Rates, Rather Than R&D Credits or Tariffs, Is Key to Supporting U.S. Biomedical Innovation
As cuts to NIH funding and Trump’s drug pricing executive order risk innovation, a new Schaeffer Center white paper analyzes how tax policies influence medical breakthroughs.
How Does Corporate Tax Policy Influence Innovation?
Corporate income tax reductions lead to more innovation within a country or state without raising overall global innovation rates, while R&D tax credits have more limited effects on innovation.